Friday, June 19, 2020 2:03:45 PM
AMNL
Prodigiosin-based nanoformulation selectively disrupts cancer cells
Reviewed by James Ives, M.Psych. (Editor)Jun 12 2020
Together with colleagues from the University of Palermo, KFU employees offer a nano preparation based on biocompatible halloysite nanotubes and bacterial pigment prodigiosin; the latter is known to selectively disrupt cancer cells without damaging the healthy ones.
"Halloysite nanotubes are known for their low toxicity in in vitro and in vivo systems and the ability to modify the outer and inner surfaces. The cavity of a nanotube can be loaded with compounds of various nature, including drugs, and modification of the ends with polymers allows the creation of targeted delivery systems with a controlled release of loaded substances," says co-author Rawil Fakhrullin, Chief Research Associate of the Bionanotechnology Lab.
The uniqueness of this new solution is its selectivity against malignant cells, unlike chemotherapy which damages mesenchymal stem cells and fibroblasts.
The pigment prodigiosin is synthesized by various microorganisms. We isolate it from the cells of the bacteria Serratia marcescens. The antibacterial, fungicidal and anticancer activity of prodigiosin is widely known, however, some of its physico-chemical properties, in particular hydrophobicity, limit the use of prodigiosin as a drug. The loading of prodigiosin into halloysite nanotubes circumvents these limitations. In addition, in the form of a nanopreparation, prodigiosin penetrates into the cells within 30 minutes. Moreover, the effect on cancer cells leads to the development of irreversible processes in them and to their death. At the same time, non-cancerous cells retain their activity and viability."
Ekaterina Naumenko, Co-author
This development paves way to better antitumor therapies with selective activity.
Source:
Kazan Federal University
Journal reference:
Guryanov, I., et al. (2020) Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation. Frontiers in Bioengineering and Biotechnology. doi.org/10.3389/fbioe.2020.00424.
https://www.news-medical.net/news/20200612/Prodigiosin-based-nanoformulation-selectively-disrupts-cancer-cells.aspx
Recent AMNL News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:38:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 10:04:24 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/05/2024 10:00:58 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM